Clinical Trials Sponsored by Hella Janssen

Total 3324 results

Janssen-Cilag, S.A.

Completed

An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder
Janssen Pharmaceutical K.K.

Terminated

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease

Dementia | Alzheimer's Disease
Janssen-Cilag, S.A.

Terminated

Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol

Gastroesophageal Reflux
Janssen-Cilag, S.A.

Terminated

Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
Janssen-Cilag, S.A.

Completed

PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
Janssen Cilag S.A.S.

Terminated

Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency

Anemia | Renal Failure, Chronic Renal Failure
Janssen Cilag S.A.S.

Terminated

Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain

Pain
Janssen Pharmaceutical K.K.

Completed

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Multiple Myeloma
Janssen Pharmaceutical K.K.

Completed

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma | Relapse | Refractory
Janssen Pharmaceutical K.K.

Completed

Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy

Ovarian Neoplasms
Janssen Pharmaceutical K.K.

Completed

Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics

Pain, Intractable
Janssen-Cilag B.V.

Completed

The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease

Anemia
Janssen-Cilag, S.A.

Completed

A Registry of Treatment Adherence for Patients With Schizophrenia

Psychotic Disorders | Schizophrenia
Janssen Pharmaceutical K.K.

Recruiting

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Japan
Janssen-Cilag Ltd.

Recruiting

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (FUZION CD)

Fistulizing Crohns Disease | Perianal Crohns Disease

Netherlands, United States, Belgium, Korea, Republic of, Taiwan, Israel, Japan, Canada, Hungary, Germany, Greece, United Kingdom, Australia, Spain, Saudi Arabia, Poland, Turkey, Portugal, Czechia, Italy, Jordan, France
Janssen-Cilag Ltd.

Not yet recruiting

A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency (POWER)

Depressive Disorder, Major

United Kingdom
Janssen Pharmaceutical K.K.

Active, not recruiting

A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan (ProPuP)

Palmoplantar Pustulosis

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies

Japan
Janssen Biotech, Inc.

Active, not recruiting

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEVELOP)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis | Indeterminate Colitis

United States, Canada
Janssen-Cilag S.p.A.

Completed

A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag (INSPECTIO)

Pulmonary Arterial Hypertension

Italy
Janssen-Cilag Ltd.

Active, not recruiting

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment (ESCAPE-LTE)

Depressive Disorder, Major

Taiwan, Turkey, Malaysia, Germany, Czechia, Korea, Republic of, Poland, Hungary, Argentina, Belgium, Bulgaria, Finland, Greece, South Africa
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (POWER)

Crohn Disease

United States, Korea, Republic of, Netherlands, France, Austria, Italy, United Kingdom, Germany, Russian Federation, Spain, Czechia, Sweden
Janssen Pharmaceutical K.K.

Completed

A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice

Ulcerative Colitis

Japan
Janssen-Cilag Ltd.

Completed

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab (STARDUST)

Crohn Disease

Belgium, Netherlands, United Kingdom, France, Czechia, Italy, Germany, Denmark, Spain, Portugal, Slovakia, Sweden
Janssen-Cilag Ltd.

Completed

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (FIRE)

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

France
Bayer
Janssen, LP

Completed

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid (XATOA)

Atherosclerosis

Germany, Argentina, Brazil, Canada, Denmark, Israel, Korea, Republic of, Lebanon, Luxembourg, Mexico, Norway, Russian Federation, Slovenia, Sweden, Switzerland, Thailand, United Arab Emirates, United Kingdom
Janssen Pharmaceutical K.K.

Withdrawn

A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Graft vs Host Disease

Japan
Janssen-Cilag S.p.A.

Completed

A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy (ARIANNA)

Suicidal Ideation | Depressive Disorder, Major

Italy
Bayer
Janssen, LP

Completed

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice (SiERRA UK)

Atrial Fibrillation

United Kingdom
Janssen-Cilag S.p.A.

Completed

A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs (SIRENA)

Spondyloarthritis, Axial and Peripheral

Italy
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-40411813 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Macitentan, in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphocytic Leukemia

Japan
Janssen Biotech, Inc.

Completed

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

Rheumatoid Arthritis | Arthritis, Psoriatic | Ankylosing Spondylitis
Janssen-Cilag Ltd.

Completed

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Schizophrenia

France, Germany, Spain, Israel, Malaysia, Turkey, Taiwan, Greece, Korea, Republic of, Russian Federation, Netherlands, United Kingdom, Croatia, Denmark, Saudi Arabia
Janssen Pharmaceutical K.K.

Completed

Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

Alzheimer's Disease

Japan
Janssen-Cilag Ltd.

Completed

Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia

Schizophrenia

France
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese Smokers

Healthy

Japan
Janssen Pharmaceutical K.K.

Withdrawn

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy | Visual Acuity

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.

Colitis, Ulcerative

Japan
Janssen-Cilag, S.A.

Terminated

Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar)

Rheumatoid Arthritis

Colombia
Janssen-Cilag Ltd.

Completed

An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection (MAPPING)

Hepatitis C Virus

Brazil
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants

Healthy

Japan

3

Subscribe